Minimal Clinically Important Difference for Safe and Simple Novel Acute Ischemic Stroke Therapies [Clinical Sciences]
Conclusions—Stroke expert responses to MCID surveys are affected by anchoring and centrality bias. When survey design takes these into account, the expert-derived MCID for a safe acute ischemic stroke treatment is 1.1% to 1.5%, in accord with actual physician behavior in guideline writing and clinical practice. This revised MCID value can guide clinical trial design and grant-funding and regulatory agency decisions.
Source: Stroke - Category: Neurology Authors: Jessica S. Cranston, Brett D. Kaplan, Jeffrey L. Saver Tags: Ischemic Stroke, Neuroprotectants Original Contributions Source Type: research
More News: Academia | Brain | Clinical Trials | Grants | Internet | Ischemic Stroke | Neurology | Stroke | USA Health | Women